SCHEMBL25547182

SCHEMBL25547182

CC(=O)NC12CC(C(=O)O)(C1)C2

nearest known ligand 0.42

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.36
GRM1 Q13255 2/20 0.35
FFAR3 O14843 1/20 0.35
PTGFR P43088 1/20 0.33
EPHX1 P07099 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4889651 0.88 PKM (0.41) ALDH1A1FFAR3
SCHEMBL11224012 0.82 KDM4E (0.37) ALDH1A1FFAR3EPHX1
SCHEMBL16118629 0.82 KDM4E (0.37) ALDH1A1FFAR3EPHX1
SCHEMBL17195153 0.79 FFAR3 (0.39) FFAR3PTGFR
SCHEMBL6229787 0.78 ALDH1A1 (0.43) ALDH1A1EPHX1
SCHEMBL6228100 0.78 ALDH1A1 (0.43) ALDH1A1EPHX1
SCHEMBL20475966 0.78 EPHX1 (0.31) FFAR3EPHX1
SCHEMBL17205413 0.77 GRM1 (0.33) GRM1PTGFR
SCHEMBL16118627 0.77 RXFP1 (0.36) ALDH1A1
SCHEMBL965747 0.77 ALDH1A1 (0.56) ALDH1A1EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4423075-B1 CCR6 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2026-03-25 EP disclosed
US-20250011313-A1 CCR6 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2025-01-09 US disclosed
EP-4423075-A1 CCR6 RECEPTOR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2024-09-04 EP disclosed
CN-118139854-A Modulators of CCR6 receptors 爱杜西亚药品有限公司 2024-06-04 CN disclosed
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2023-11-09 US disclosed
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed
WO-2023073082-A1 CCR6 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2023-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011313-A1 CCR6 RECEPTOR MODULATORS CCR6, CCR1, CCR4 ALDH1A1 1705/4885GRM1 222/4885FFAR3 247/4885
US-20230357158-A1 QUINOLINE cGAS ANTAGONIST COMPOUNDS CGAS, GLS2, GLS ALDH1A1 4236/4885GRM1 720/4885FFAR3 1191/4885
US-20230159504-A1 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINB1, SERPINE1 ALDH1A1 542/4885GRM1 3781/4885FFAR3 4786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.